Intravenous Magnesium Sulfate Enhances the Ability of Intravenous Ibutilide to Successfully Convert Atrial Fibrillation or Flutter
- 29 October 2007
- journal article
- research article
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 30 (11) , 1331-1335
Abstract
Background: A previous randomized trial found that adjunctive use of intravenous magnesium (a total of 4 grams) can attenuate the corrected QT interval (QTc) prolongation associated with ibutilide, but its impact on ibutilide efficacy has not been elucidated. Methods: This was a cohort evaluation of 229 consecutive patients who received ibutilide in the presence or absence of intravenous magnesium. Multivariate logistic regression analysis was used to determine the impact of magnesium on ibutilide efficacy as well as the impact of magnesium dosing intensity on ibutilide efficacy. Results: The overall chemical conversion rate with ibutilide in the presence or absence of magnesium was 59.8%. The concurrent administration of magnesium (n = 141) was associated with a 78% increased odds of successful chemical conversion (adjusted odds ratio, AOR; 1.78 [95% confidence intervals,CI 1.02–3.09]) compared to those who did not receive magnesium (n = 88). Magnesium dosing intensity appeared to be an important determinant of ibutilide efficacy, with the 4 grams dose associated with a threefold increase in the odds of successful chemical conversion (AOR; 2.98 [95% CI 1.46–6.11). The 1 to 3 grams subgroup was associated with only a trend toward an improvement. There was only one case of Torsade de Pointes (TdP) which occurred in the no adjunctive magnesium group. Conclusions: Concurrent use of magnesium enhanced the ability of ibutilide to successfully convert atrial fibrillation (AF) or flutter (AFl). The 4 grams magnesium dose appeared to provide the greatest benefit.Keywords
This publication has 26 references indexed in Scilit:
- ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial FibrillationJACC, 2006
- Impact of Intravenous Magnesium on Post-Cardiothoracic Surgery Atrial Fibrillation and Length of Hospital Stay: A Meta-AnalysisThe Annals of Thoracic Surgery, 2005
- Model of effect of magnesium prophylaxis on frequency of torsades de pointes in ibutilide-treated patientsAmerican Journal of Health-System Pharmacy, 2004
- Impact of prophylactic i.v. magnesium on the efficacy of ibutilide for conversion of atrial fibrillation or flutterAmerican Journal of Health-System Pharmacy, 2003
- Effects of Intravenous Magnesium Sulfate on the QT Interval in Patients Receiving IbutilidePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillationInternational Journal of Cardiology, 2001
- Efficacy and Safety of Ibutilide Fumarate for the Conversion of Atrial Arrhythmias After Cardiac SurgeryCirculation, 1999
- Prophylactic Magnesium to Decrease the Arrhythmogenic Potential of Class III Antiarrhythmic Agents in a Rabbit ModelPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1999
- Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmiasCritical Care Medicine, 1995
- Magnesium therapy in new-onset atrial fibrillationThe American Journal of Cardiology, 1994